AR068385A1 - Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina - Google Patents

Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina

Info

Publication number
AR068385A1
AR068385A1 ARP080103905A ARP080103905A AR068385A1 AR 068385 A1 AR068385 A1 AR 068385A1 AR P080103905 A ARP080103905 A AR P080103905A AR P080103905 A ARP080103905 A AR P080103905A AR 068385 A1 AR068385 A1 AR 068385A1
Authority
AR
Argentina
Prior art keywords
optionally
association
conversion enzyme
active metabolite
angiotensin conversion
Prior art date
Application number
ARP080103905A
Other languages
English (en)
Inventor
Tony Verbeuren
Patricia Sansilvestri-Morel
Alain Rupin
Marie-Odile Vallez
Gilbert Lavielle
Laurence Lerond
Marie-Dominique Fratacci
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR068385A1 publication Critical patent/AR068385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Asociacion de un antiaterotrombotico y de un inhibidor de la enzima de conversion de la angiotensina (IECA), así como las composiciones farmacéuticas que la contienen. Reivindicacion 1: Asociacion del compuesto de la formula (1) opcionalmente bajo la forma de isomero optico o de una de sus sales farmacéuticamente aceptable y de un inhibidor de la enzima de conversion de la angiotensina o de una de sus sales farmacéuticamente aceptable. Reivindicacion 4: Asociacion segun una cualquiera de las reivindicaciones 1, 2 o 3, caracterizada porque el inhibidor de la enzima de conversion de la angiotensina es perindopril opcionalmente bajo la forma de su metabolito activo el perindoprilato, ramipril opcionalmente bajo la forma de su metabolito activo el ramiprilato, enalapril opcionalmente bajo la forma de su metabolito activo el enalaprilato, captopril, lisinopril, delapril, fosinopril, quinapril, espirapril, imidapril, trandolapril opcionalmente bajo la forma de su metabolito activo el trandolaprilato, benazepril, cilazapril, temocapril, alacepril, ceronapril, moveltipril o moexipril, así como sus sales de adicion de un ácido o una base farmacéuticamente aceptable.
ARP080103905A 2007-09-11 2008-09-09 Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina AR068385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706345A FR2920772B1 (fr) 2007-09-11 2007-09-11 Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Publications (1)

Publication Number Publication Date
AR068385A1 true AR068385A1 (es) 2009-11-11

Family

ID=39366989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103905A AR068385A1 (es) 2007-09-11 2008-09-09 Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina

Country Status (27)

Country Link
US (1) US20090075976A1 (es)
EP (1) EP2036886A1 (es)
JP (1) JP2009067793A (es)
KR (1) KR20090027167A (es)
CN (1) CN101385723A (es)
AP (1) AP2008004590A0 (es)
AR (1) AR068385A1 (es)
AU (1) AU2008207584A1 (es)
BR (1) BRPI0804140A2 (es)
CA (1) CA2638354A1 (es)
CL (1) CL2008002653A1 (es)
CO (1) CO6020018A1 (es)
CR (1) CR10228A (es)
EA (1) EA200801829A1 (es)
EC (1) ECSP088713A (es)
FR (1) FR2920772B1 (es)
GT (2) GT200800169A (es)
IL (1) IL193585A0 (es)
MA (1) MA30374B1 (es)
MX (1) MX2008011329A (es)
NZ (1) NZ571144A (es)
PA (1) PA8795401A1 (es)
PE (1) PE20090941A1 (es)
SG (1) SG151171A1 (es)
TW (1) TW200920354A (es)
UY (1) UY31304A1 (es)
WO (1) WO2009066035A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130190370A1 (en) 2010-07-29 2013-07-25 The Trustees Of The University Of Pennsylvania Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor
CN109248319A (zh) * 2017-07-14 2019-01-22 郜建敏 含有司坦类化合物和阿司匹林的药物组合物
MX2021003090A (es) * 2018-09-18 2021-05-12 Lilly Co Eli Sal de erbumina de treprostinil.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
FR2857593B1 (fr) * 2003-07-18 2005-10-14 Servier Lab Composition pharmaceutique orodispersible d'un compose antithrombotique
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
KR20090027167A (ko) 2009-03-16
EP2036886A1 (fr) 2009-03-18
ECSP088713A (es) 2008-10-31
UY31304A1 (es) 2008-09-30
GT200800169A (es) 2010-05-21
JP2009067793A (ja) 2009-04-02
WO2009066035A3 (fr) 2009-08-27
CA2638354A1 (fr) 2009-03-11
MA30374B1 (fr) 2009-05-04
PA8795401A1 (es) 2009-04-23
GT200800178A (es) 2010-07-02
MX2008011329A (es) 2009-03-10
EA200801829A1 (ru) 2009-06-30
TW200920354A (en) 2009-05-16
CL2008002653A1 (es) 2009-06-05
WO2009066035A2 (fr) 2009-05-28
CN101385723A (zh) 2009-03-18
AU2008207584A1 (en) 2009-03-26
NZ571144A (en) 2010-01-29
AP2008004590A0 (en) 2008-08-31
CO6020018A1 (es) 2009-03-31
FR2920772B1 (fr) 2009-10-23
CR10228A (es) 2009-04-28
FR2920772A1 (fr) 2009-03-13
US20090075976A1 (en) 2009-03-19
PE20090941A1 (es) 2009-07-18
BRPI0804140A2 (pt) 2009-06-16
SG151171A1 (en) 2009-04-30
IL193585A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NZ701609A (en) Liquid formulation comprising propylene glycol and an inodilator
JP2018507244A5 (es)
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
CO6382125A2 (es) Inhibidores de proteína quinasa
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
EA026892B9 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
MX2013006083A (es) Derivados de 6-amino-2-fenilamino-1h-bencimidazola-5-carboxamida y sus uso como inhibidores de prostaglandina e2 sintasa-1 microsomal.
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
CR20110224A (es) Pirazolopirimidina inhibidor jak compuestos y metodos
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
UY31189A1 (es) Compuestos heterocíclicos
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
EA201390347A1 (ru) Лечение заболеваний
CR20120318A (es) Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a
BR112012019042A2 (pt) "inibidores de serina protease tipo tripsina, e sua preparação e uso".
NI201000159A (es) Cápsula para la prevención de enfermedades cardiovasculares.
CY1117261T1 (el) [4-(5-αμινομεθυλο-2-φθορο-φαινυλο)-πιπεριδιν-1-υλο]-[7-φθορο-1-(2-μεθοξυ-αιθυλο)-4τριφθορο μεθοξυ-1η-ινδολ-3-υλο]-μεθανονη ως αναστολεας τρυπτασης maστοκυτταρων
UA100393C2 (ru) Новые офтальмологические композиции
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
AR068385A1 (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina
TR201005325A2 (tr) Atorvastatin ve aspirin içeren farmasötik formülasyonlar
EA201001823A1 (ru) Новые гетероциклические карбоксамиды для применения в качестве ингибиторов тромбина
PT2480232E (pt) [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]- metanonas dissubstituídas
HN2010000533A (es) Nuevas sales de adicion de inhibidores de la enzima de conversion de la angiotensina a acidos donadores de no, procedimiento de preparacion y las composiciones farmaceuticas que las contienen
WO2008156832A3 (en) Renin inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal